Importantly, decreased expression of the LATS2L signature was correlated with reduced survival of luminal breast cancer patients (Fig 1D); furthermore, low LATS2 mRNA was associated with decreased probability of relapse-free survival among lumB patients (Fig S1B). This evidence concerns the gene LATS2 and breast carcinoma.